CDRI sees its mission in enabling discovery and development of innovative therapies for unmet needs utilizing highest expertise and innovation potential of Russian scientists with integrated external R&D solutions of Discovery outSourceTM platforms. CDRI’s expertise in rational drug design, synthetic and medicinal chemistry in various therapeutic areas of target classes has allowed it to successfully execute collaborations with leading Pharmaceutical and Biotechnology companies leveraging company’s core capabilities in chemistry and biology.
As a pioneer in discovery libraries, CDRI has started its diverse collection in 1991 by compiling heterocyclic compounds from all over the world, and later launching its own large-scale library synthesis program. Today, CDRI is the global leader in discovery chemistry. The company has built the industry’s largest and most diverse collection of over 1,500,000 individually crafted, lead-like, drug-like small molecules. This collection is steadily growing at a rate of over 16,000 compounds a month, exclusively synthesized in-house. CDRI’s novel chemistry is designed by a group of experts and is finely balanced with maximal diversity, bioactivity against particular targets, template novelty and robust IP position.
Hit Seeking: With a total collection of over one million small molecule compounds, our screening libraries can be instrumental for hit-finding programs. Ten percent of the total collection is dedicated to specific target areas, further focusing screening efforts in a cost-effective and expeditious way. For biological assay assistance, CDRI offers drug discovery services as a compliment to our extensive collection. We have especially extensive experience in the therapeutic areas of CNS, oncology, and metabolism. In addition to assay-driven hit-finding, CDRI is well equipped to implement the process in silica. Ligand docking/scoring approaches can be explored with computer assisted drug design (CADD) programs. When the 3-dimensional structure of the target is known, CDRI facilitates hit-finding with our fragment-based drug design library coupled with our ability to conduct protein cloning, expression, purification, co/crystallization and x-ray crystallography.
Hit to Lead Development: Hit compounds are often not very « drug-like ». They likely suffer from one or more problems that render them unsuitable for use in animals. To remedy the situation, medicinal chemists at CDRI have devised useful medicinal chemistry filters that eliminate compounds with problematic features from a large pool of hits. Traditional biology-driven lead development is complemented by our team of exceptionally skilled synthetic chemists who strive to provide compounds with desirable lead properties.
Lead Optimization: From a substantial set of hit compounds, a smaller number have been culled which can be referred to as lead compounds. Now it is time to optimize these leads in the hopes of obtaining substances that can be administered to humans. Many of the features of hit to lead development are often continued during this phase, but in addition, close scrutiny is applied to preclinical development in vivo properties such as DMPK, toxicity and safety. Formulation issues and the intellectual property potential of emerging drug compounds also receive profound attention at this point.
One of the industry’s most established CROs, Chemical Diversity Group offers Integrated Discovery outSource solutions that cover a complete range of disciplines needed to bring a new project in CNS, oncology, inflammation, metabolic, infectious and other diseases from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate (Phase I and II) and to the market. With successful 20 years business record in life sciences and over 500 research associates employed globally, we put forward unique translational capabilities from Research to Clinical Development.